Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis

Detalhes bibliográficos
Autor(a) principal: Andres,Marina Paula
Data de Publicação: 2019
Outros Autores: Mendes,Renata Franco Pimentel, Hernandes,Camila, Araújo,Sérgio Eduardo Alonso, Podgaec,Sérgio
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Einstein (São Paulo)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000200213
Resumo: ABSTRACT Objective: To evaluate clinical features and complications in patients with bowel endometriosis submitted to hormonal therapy. Methods: Retrospective study based on data extracted from medical records of 238 women with recto-sigmoid endometriosis treated between May 2010 and May 2016. Results: Over the course of follow-up, 143 (60.1%) women remained in medical treatment while 95 (39.9%) presented with worsening of pain symptoms or intestinal lesion growth (failure of medical treatment group), with surgical resection performed in 54 cases. Women in the Medical Treatment Group were older (40.5±5.1 years versus 37.3±5.8 years; p<0.0001) and had smaller recto sigmoid lesions (2.1±1.9 versus 3.1±2.2; p=0.008) compared to those who had failed to respond to medical treatment. Similar significant reduction in pain scores for dysmenorrhea, chronic pelvic pain, cyclic dyschezia and dysuria was observed in both groups; however greater reduction in pain scores for dyspareunia was noted in the Surgical Group. Subjective improvement in pain symptoms was also similar between groups (100% versus 98.2%; p=0.18). Major complications rates were higher in the Surgical Group (9.2% versus 0.6%; p=0.001). Conclusion: Patients with recto-sigmoid endometriosis who failed to respond to medical treatment were younger and had larger intestinal lesions. Hormonal therapy was equally efficient in improving pain symptoms other than dyspareunia compared to surgery, and was associated with lower complication rates in women with recto-sigmoid endometriosis. Medical treatment should be offered as a first-line therapy for patients with bowel endometriosis. Surgical treatment should be reserved for patients with pain symptoms unresponsive to hormonal therapy, lesion growth or suspected intestinal subocclusion.
id IIEPAE-1_fcbd2ffb7e5f846e6d030f509c99464a
oai_identifier_str oai:scielo:S1679-45082019000200213
network_acronym_str IIEPAE-1
network_name_str Einstein (São Paulo)
repository_id_str
spelling Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosisEndometriosis/therapyUltrasonographySigmoid diseasesHormones/therapeutic useContraceptives, oral, combinedProgestinsPelvic painABSTRACT Objective: To evaluate clinical features and complications in patients with bowel endometriosis submitted to hormonal therapy. Methods: Retrospective study based on data extracted from medical records of 238 women with recto-sigmoid endometriosis treated between May 2010 and May 2016. Results: Over the course of follow-up, 143 (60.1%) women remained in medical treatment while 95 (39.9%) presented with worsening of pain symptoms or intestinal lesion growth (failure of medical treatment group), with surgical resection performed in 54 cases. Women in the Medical Treatment Group were older (40.5±5.1 years versus 37.3±5.8 years; p<0.0001) and had smaller recto sigmoid lesions (2.1±1.9 versus 3.1±2.2; p=0.008) compared to those who had failed to respond to medical treatment. Similar significant reduction in pain scores for dysmenorrhea, chronic pelvic pain, cyclic dyschezia and dysuria was observed in both groups; however greater reduction in pain scores for dyspareunia was noted in the Surgical Group. Subjective improvement in pain symptoms was also similar between groups (100% versus 98.2%; p=0.18). Major complications rates were higher in the Surgical Group (9.2% versus 0.6%; p=0.001). Conclusion: Patients with recto-sigmoid endometriosis who failed to respond to medical treatment were younger and had larger intestinal lesions. Hormonal therapy was equally efficient in improving pain symptoms other than dyspareunia compared to surgery, and was associated with lower complication rates in women with recto-sigmoid endometriosis. Medical treatment should be offered as a first-line therapy for patients with bowel endometriosis. Surgical treatment should be reserved for patients with pain symptoms unresponsive to hormonal therapy, lesion growth or suspected intestinal subocclusion.Instituto Israelita de Ensino e Pesquisa Albert Einstein2019-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000200213einstein (São Paulo) v.17 n.2 2019reponame:Einstein (São Paulo)instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)instacron:IIEPAE10.31744/einstein_journal/2019ao4583info:eu-repo/semantics/openAccessAndres,Marina PaulaMendes,Renata Franco PimentelHernandes,CamilaAraújo,Sérgio Eduardo AlonsoPodgaec,Sérgioeng2019-04-29T00:00:00Zoai:scielo:S1679-45082019000200213Revistahttps://journal.einstein.br/pt-br/ONGhttps://old.scielo.br/oai/scielo-oai.php||revista@einstein.br2317-63851679-4508opendoar:2019-04-29T00:00Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)false
dc.title.none.fl_str_mv Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis
title Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis
spellingShingle Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis
Andres,Marina Paula
Endometriosis/therapy
Ultrasonography
Sigmoid diseases
Hormones/therapeutic use
Contraceptives, oral, combined
Progestins
Pelvic pain
title_short Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis
title_full Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis
title_fullStr Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis
title_full_unstemmed Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis
title_sort Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis
author Andres,Marina Paula
author_facet Andres,Marina Paula
Mendes,Renata Franco Pimentel
Hernandes,Camila
Araújo,Sérgio Eduardo Alonso
Podgaec,Sérgio
author_role author
author2 Mendes,Renata Franco Pimentel
Hernandes,Camila
Araújo,Sérgio Eduardo Alonso
Podgaec,Sérgio
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Andres,Marina Paula
Mendes,Renata Franco Pimentel
Hernandes,Camila
Araújo,Sérgio Eduardo Alonso
Podgaec,Sérgio
dc.subject.por.fl_str_mv Endometriosis/therapy
Ultrasonography
Sigmoid diseases
Hormones/therapeutic use
Contraceptives, oral, combined
Progestins
Pelvic pain
topic Endometriosis/therapy
Ultrasonography
Sigmoid diseases
Hormones/therapeutic use
Contraceptives, oral, combined
Progestins
Pelvic pain
description ABSTRACT Objective: To evaluate clinical features and complications in patients with bowel endometriosis submitted to hormonal therapy. Methods: Retrospective study based on data extracted from medical records of 238 women with recto-sigmoid endometriosis treated between May 2010 and May 2016. Results: Over the course of follow-up, 143 (60.1%) women remained in medical treatment while 95 (39.9%) presented with worsening of pain symptoms or intestinal lesion growth (failure of medical treatment group), with surgical resection performed in 54 cases. Women in the Medical Treatment Group were older (40.5±5.1 years versus 37.3±5.8 years; p<0.0001) and had smaller recto sigmoid lesions (2.1±1.9 versus 3.1±2.2; p=0.008) compared to those who had failed to respond to medical treatment. Similar significant reduction in pain scores for dysmenorrhea, chronic pelvic pain, cyclic dyschezia and dysuria was observed in both groups; however greater reduction in pain scores for dyspareunia was noted in the Surgical Group. Subjective improvement in pain symptoms was also similar between groups (100% versus 98.2%; p=0.18). Major complications rates were higher in the Surgical Group (9.2% versus 0.6%; p=0.001). Conclusion: Patients with recto-sigmoid endometriosis who failed to respond to medical treatment were younger and had larger intestinal lesions. Hormonal therapy was equally efficient in improving pain symptoms other than dyspareunia compared to surgery, and was associated with lower complication rates in women with recto-sigmoid endometriosis. Medical treatment should be offered as a first-line therapy for patients with bowel endometriosis. Surgical treatment should be reserved for patients with pain symptoms unresponsive to hormonal therapy, lesion growth or suspected intestinal subocclusion.
publishDate 2019
dc.date.none.fl_str_mv 2019-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000200213
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000200213
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.31744/einstein_journal/2019ao4583
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
dc.source.none.fl_str_mv einstein (São Paulo) v.17 n.2 2019
reponame:Einstein (São Paulo)
instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
instname_str Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron_str IIEPAE
institution IIEPAE
reponame_str Einstein (São Paulo)
collection Einstein (São Paulo)
repository.name.fl_str_mv Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
repository.mail.fl_str_mv ||revista@einstein.br
_version_ 1752129909633843200